Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Telix Pharmaceuticals LimitedTelephone
61.3.9093.3855
Address
North Melbourne Suite 401 55 Flemington Road Melbourne, Victoria (VIC) 3051
Description
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 8.2 - 20.76
Trade Value (12mth)
AU$3,855,862.00
1 week
0.47%
1 month
1.64%
YTD
90.67%
1 year
73%
All time high
20.76
EPS 3 yr Growth
-109.300%
EBITDA Margin
11.60%
Operating Cashflow
$24m
Free Cash Flow Return
18.80%
ROIC
4.10%
Interest Coverage
59.00
Quick Ratio
1.30
Shares on Issue (Fully Dilluted)
332m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
1.99
Date | Announcements |
---|---|
24 July 24 |
Telix Successfully Prices A$650M Convertible Bonds
×
Telix Successfully Prices A$650M Convertible Bonds |
24 July 24 |
Appendix 3B
×
Appendix 3B |
24 July 24 |
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
×
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent |
23 July 24 |
Telix Announces A$600 Million Convertible Bonds Offering
×
Telix Announces A$600 Million Convertible Bonds Offering |
23 July 24 |
Telix Investor Presentation July 2024
×
Telix Investor Presentation July 2024 |
18 July 24 |
Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade
×
Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade |
11 July 24 |
CMS proposes payment improvement for radiopharma diagnostics
×
CMS proposes payment improvement for radiopharma diagnostics |
10 July 24 |
Notification of cessation of securities - TLX
×
Notification of cessation of securities - TLX |
04 July 24 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
04 July 24 |
Cleansing Notice
×
Cleansing Notice |
03 July 24 |
Pending Release of Shares from Voluntary Escrow
×
Pending Release of Shares from Voluntary Escrow |
03 July 24 |
Ceasing to be a substantial holder from MUFG
×
Ceasing to be a substantial holder from MUFG |
03 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
02 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
02 July 24 |
Ceasing to be a substantial holder from MS
×
Ceasing to be a substantial holder from MS |
02 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
02 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
27 June 24 |
Notification regarding unquoted securities - TLX
×
Notification regarding unquoted securities - TLX |
27 June 24 |
Appendix 3Y Change in Director Interests - C Behrenbruch
×
Appendix 3Y Change in Director Interests - C Behrenbruch |
27 June 24 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
27 June 24 |
Cleansing Notice
×
Cleansing Notice |
14 June 24 |
Telix Elects to Withdraw from Proposed U.S. Listing
×
Telix Elects to Withdraw from Proposed U.S. Listing |
13 June 24 |
Trading Halt
×
Trading Halt |
06 June 24 |
Telix Launches Proposed US IPO
×
Telix Launches Proposed US IPO |
03 June 24 |
Telix Completes TLX250-CDx (Zircaix) BLA Submission
×
Telix Completes TLX250-CDx (Zircaix) BLA Submission |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.